WE KNOW COLLAGEN
THAT'S WHY WE ADDED SOMETHING
IMPORTANT: ORC

PROMOGRAN® &
PROMOGRAN PRISMA®
WHAT ARE THEY?

PROMOGRAN® Protease Modulating Matrix is comprised of a sterile, freeze dried composite of 45% oxidized regenerated cellulose (ORC) and 55% collagen.

PROMOGRAN PRISMA® Wound Balancing Matrix is comprised of a sterile, freeze dried composite of 44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC. Silver-ORC contains 25% w/w ionically bound silver, a well-known antimicrobial agent.

OPTIMUM WOUND HEALING ENVIRONMENT

PROMOGRAN® and PROMOGRAN PRISMA® maintain an optimal wound healing environment. This environment is conducive to granulation tissue formation, epithelisation and rapid wound healing.

CLINICALLY PROVEN

The efficacy of PROMOGRAN® and PROMOGRAN PRISMA® is supported by a large body of clinical evidence, including 10 published RCTs.

COST-EFFECTIVENESS

A retrospective clinical study on chronic wounds from different aetiologies (n=974) demonstrated that sequential wound management with PROMOGRAN PRISMA® and PROMOGRAN® was more cost-effective than treatment with gauze dressings over a 2-month period. The cost advantage was attributed to reduced nursing time and improved healing rate.
Several RCTs have reported superior results when using PROMOGRAN® or PROMOGRAN PRISMA® versus standard of care in chronic wounds\textsuperscript{18-21}.

In a 6-week RCT involving patients with PUs (n=80), patients in the PROMOGRAN® group had 68\% less dressing changes, compared to the Control group (moist wound healing)\textsuperscript{22}.

In a 6-week RCT comparing the use of PROMOGRAN® to moist wound healing (Control) in PUs (n=80), patients in the PROMOGRAN® group experienced a shorter hospitalisation time compared to Control (360 days overall hospitalisation vs 1164 days in Control group)\textsuperscript{22}.

A 12-week RCT involving VLU patients (n=73) found that wounds in the PROMOGRAN® group experienced a significantly greater reduction in wound areas compared to Control (54.4\% vs 36.5\%, p<0.0001)\textsuperscript{19}.

**Study withdrawals due to infection**

14 week study on diabetic foot ulcers\textsuperscript{21}

In a 14-week RCT (n=40) comparing PROMOGRAN PRISMA® with best standard of care (Control) in DFUs, the number of wounds withdrawn from the study due to infection was significantly greater in the Control group (0\% vs 31\%, p=0.012)\textsuperscript{21}.

...and is also more cost effective...

An additional retrospective study analyzing cost-effectiveness in the management of neuropathic DFU (n=40), showed that wound management with PROMOGRAN® was more cost-effective per patient over 6 weeks of treatment as compared to standard care (Control)\textsuperscript{23}.
WHEN TO USE THEM?

PROMOGRAN® and PROMOGRAN PRISMA® are indicated for the management of all wounds healing by secondary intent which are clear of necrotic tissue, including:

- Diabetic ulcers
- Venous ulcers
- Pressure ulcers
- Ulcers caused by mixed vascular aetiologies
- Traumatic and surgical wounds

PROMOGRAN® and PROMOGRAN PRISMA® have demonstrated haemostatic properties.

PROMOGRAN® and PROMOGRAN PRISMA® can be used under compression therapy.

<table>
<thead>
<tr>
<th>Size</th>
<th>Dressings per carton</th>
<th>Product code</th>
</tr>
</thead>
<tbody>
<tr>
<td>28cm²</td>
<td>10</td>
<td>PS2028</td>
</tr>
<tr>
<td>123cm²</td>
<td>10</td>
<td>PS2123</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Size</th>
<th>Dressings per carton</th>
<th>Product code</th>
</tr>
</thead>
<tbody>
<tr>
<td>28cm²</td>
<td>10</td>
<td>M772028</td>
</tr>
<tr>
<td>123cm²</td>
<td>10</td>
<td>M772123</td>
</tr>
</tbody>
</table>